NDAINJECTIONINJECTABLE
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Iodohippurate Sodium I-131 is a radiopharmaceutical diagnostic agent containing iodine-131, used for renal imaging and assessment of kidney function. Administered via injection, it localizes in the kidneys to visualize perfusion and clearance patterns. This product is in pre-launch phase under sponsor PharmaLundensis.
Pre-Launch
Early-stage radiopharmaceutical with limited commercial data; team build and market entry strategy will be primary focus.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This pre-launch radiopharmaceutical offers entry-level and mid-career professionals opportunity to build expertise in nuclear medicine diagnostics and regulatory pathways. Career progression will depend on successful approval and market penetration in the renal imaging space.
Regulatory Affairs ManagerMedical Science Liaison
Worked on IODOHIPPURATE SODIUM I 131 at PharmaLundensis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.